Current Therapies and Future Directions in Treatment of Glioblastoma

Chapter
Part of the Current Cancer Research book series (CUCR)

Abstract

The current standard of care for initial treatment of adults with newly diagnosed glioblastoma (GBM) constitutes maximal safe resection followed by concurrent chemoradiation therapy and adjuvant chemotherapy with temozolomide; recent studies have shown improvement in survival benefit with the addition of tumor treatment fields (TTF) to this regimen. For recurrent disease, lomustine and bevacizumab yield benefit in progression-free survival but not in overall survival. Recent advances in the understanding of the biology of GBM have provided the basis for new therapeutic approaches against these tumors. However, the initial promise of agents targeted against specific pathways active in GBM failed to yield the expected improvement in outcome likely due to intra- and inter-tumoral heterogeneity. Current efforts are focused on immunotherapy, biological agents and combination targeted therapies to overcome these challenges. Additionally, ongoing research to better understand the basis of tumor heterogeneity is expected to provide new insights that can help broadly target GBMs that can translate into improved survival and quality of life for these patients. This review provides an outline of current treatments and examines the newer approaches that bear promise to provide a meaningful improvement in outcome of patients with GBM.

Keywords

Glioblastoma Targeted Agents Antiangiogenic agents Biological therapies Immunotherapy 

References

  1. Alegre, M.L., K.A. Frauwirth, and C.B. Thompson. 2001. T-cell regulation by CD28 and CTLA-4. Nature Reviews. Immunology 1(3): 220–228. doi: 10.1038/35105024.
  2. Andersen, A.P. 1978. Postoperative irradiation of glioblastomas. Results in a randomized series. Acta Radiologica: Oncology, Radiation, Physics, Biology 17 (6): 475–484.Google Scholar
  3. Barbarite, E., J.T. Sick, E. Berchmans, A. Bregy, A.H. Shah, N. Elsayyad, and R.J. Komotar. 2016. The role of brachytherapy in the treatment of glioblastoma multiforme. Neurosurgical Review 40 (2): 195–211. doi: 10.1007/s10143-016-0727-6.CrossRefPubMedGoogle Scholar
  4. Batchelor, T.T., P. Mulholland, B. Neyns, L.B. Nabors, M. Campone, A. Wick, et al. 2013. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of Clinical Oncology 31 (26): 3212–3218. doi: 10.1200/JCO.2012.47.2464.CrossRefPubMedPubMedCentralGoogle Scholar
  5. Bennouna, J., J. Sastre, D. Arnold, P. Osterlund, R. Greil, E. Van Cutsem, et al. 2013. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial. The Lancet Oncology 14 (1): 29–37. doi: 10.1016/S1470-2045(12)70477-1.CrossRefPubMedGoogle Scholar
  6. van den Bent, M.J., A.A. Brandes, R. Rampling, M.C. Kouwenhoven, J.M. Kros, A.F. Carpentier, et al. 2009. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. Journal of Clinical Oncology 27 (8): 1268–1274. doi: 10.1200/JCO.2008.17.5984.CrossRefPubMedPubMedCentralGoogle Scholar
  7. Bloch, O., C.A. Crane, Y. Fuks, R. Kaur, M.K. Aghi, M.S. Berger, et al. 2014. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: A phase II, single-arm trial. Neuro-Oncology 16: 274–910.1093. doi: 10.1093/neuonc/not203.
  8. Brandes, A.A., A. Tosoni, P. Amista, L. Nicolardi, D. Grosso, F. Berti, et al. 2004. How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial. Neurology 63 (7): 1281–1284.CrossRefPubMedGoogle Scholar
  9. Brandes, A.A., A. Tosoni, E. Franceschi, V. Blatt, A. Santoro, M. Faedi, et al. 2009a. Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: A phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemotherapy and Pharmacology 64 (4): 769–775. doi: 10.1007/s00280-009-0926-8.CrossRefPubMedPubMedCentralGoogle Scholar
  10. Brandes, A.A., E. Franceschi, A. Tosoni, F. Benevento, L. Scopece, V. Mazzocchi, et al. 2009b. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: Correlation with MGMT promoter methylation status. Cancer 115 (15): 3512–3518. doi: 10.1002/cncr.24406.CrossRefPubMedGoogle Scholar
  11. Brem, H., S. Piantadosi, P.C. Burger, M. Walker, R. Selker, N.A. Vick, et al. 1995. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet. 345 (8956): 1008–1012.PubMedGoogle Scholar
  12. Brennan, C.W., R.G. Verhaak, A. McKenna, B. Campos, H. Noushmehr, S.R. Salama, et al. 2013. The somatic genomic landscape of glioblastoma. Cell 155 (2): 462–477. doi: 10.1016/j.cell.2013.09.034.CrossRefPubMedPubMedCentralGoogle Scholar
  13. Brown, P.D., S. Krishnan, J.N. Sarkaria, W. Wu, K.A. Jaeckle, J.H. Uhm, et al. 2008. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. Journal of Clinical Oncology 26 (34): 5603–5609. doi: 10.1200/JCO.2008.18.0612.CrossRefPubMedPubMedCentralGoogle Scholar
  14. Buckner, J.C. 2003. Factors influencing survival in high-grade gliomas. Seminars in Oncology 30 (6 Suppl 19): 10–14.CrossRefPubMedGoogle Scholar
  15. Cabrera, A.R., K.C. Cuneo, A. Desjardins, J.H. Sampson, F. McSherry, J.E. Herndon 2nd, et al. 2013. Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: A prospective trial. International Journal of Radiation Oncology, Biology, Physics 86 (5): 873–879. doi: 10.1016/j.ijrobp.2013.04.029.CrossRefPubMedGoogle Scholar
  16. Celldex, Public Communication. 2016. http://ir.celldex.com/releasedetail.cfm?ReleaseID=959021.
  17. Chan, J.L., S.W. Lee, B.A. Fraass, D.P. Normolle, H.S. Greenberg, L.R. Junck, et al. 2002. Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. Journal of Clinical Oncology 20 (6): 1635–1642.CrossRefPubMedGoogle Scholar
  18. Chang, S.M., P. Wen, T. Cloughesy, H. Greenberg, D. Schiff, C. Conrad, et al. 2005. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Investigational New Drugs 23 (4): 357–361. doi: 10.1007/s10637-005-1444-0.CrossRefPubMedGoogle Scholar
  19. Chinot, O.L., W. Wick, W. Mason, R. Henriksson, F. Saran, R. Nishikawa, et al. 2014. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. The New England Journal of Medicine 370 (8): 709–722. doi: 10.1056/NEJMoa1308345.CrossRefPubMedGoogle Scholar
  20. Chiocca, E.A., K.M. Abbed, S. Tatter, et al. 2004. A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Molecular Therapy 10: 958–966.CrossRefPubMedGoogle Scholar
  21. Chiocca, E.A., L.K. Aguilar, S.D. Bell, et al. 2011. Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma. Journal of Clinical Oncology 29: 3611–3619.CrossRefPubMedPubMedCentralGoogle Scholar
  22. Choe, G., S. Horvath, T.F. Cloughesy, K. Crosby, D. Seligson, A. Palotie, et al. 2003. Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Research 63 (11): 2742–2746.PubMedGoogle Scholar
  23. Choucair, A.K., V.A. Levin, P.H. Gutin, R.L. Davis, P. Silver, M.S. Edwards, et al. 1986. Development of multiple lesions during radiation therapy and chemotherapy in patients with gliomas. Journal of Neurosurgery 65 (5): 654–658. doi: 10.3171/jns.1986.65.5.0654.CrossRefPubMedGoogle Scholar
  24. Combs, S.E., J. Wagner, M. Bischof, T. Welzel, F. Wagner, J. Debus, et al. 2008. Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients. International Journal of Radiation Oncology, Biology, Physics 70 (4): 987–992. doi: 10.1016/j.ijrobp.2007.07.2368.CrossRefPubMedGoogle Scholar
  25. Cozad, S.C., P. Townsend, R.A. Morantz, A.B. Jenny, J.J. Kepes, and S.R. Smalley. 1996. Gliomatosis cerebri. Results with radiation therapy. Cancer 78 (8): 1789–1793.CrossRefPubMedGoogle Scholar
  26. Crane, C.A., S.J. Han, B. Ahn, J. Oehlke, V. Kivett, A. Fedoroff, et al. 2013. Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein. Clinical Cancer Research 19: 205–214. doi:10.1158/1078-0432.ccr-11-3358.Google Scholar
  27. Del Vecchio, C.A., C.P. Giacomini, H. Vogel, K.C. Jensen, T. Florio, A. Merlo, et al. 2013. EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms. Oncogene 32 (21): 2670–2681. doi: 10.1038/onc.2012.280.CrossRefPubMedGoogle Scholar
  28. Engelman, J.A. 2009. Targeting PI3K signalling in cancer: Opportunities, challenges and limitations. Nature Reviews. Cancer 9 (8): 550–562. doi: 10.1038/nrc2664.CrossRefPubMedGoogle Scholar
  29. Eshhar, Z., T. Waks, G. Gross, and D.G. Schindler. 1993. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proceedings of the National Academy of Sciences of the United States of America 90: 720–410.CrossRefPubMedPubMedCentralGoogle Scholar
  30. Esteller, M., J. Garcia-Foncillas, E. Andion, S.N. Goodman, Hidalgo OF, V. Vanaclocha, et al. 2000. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. The New England Journal of Medicine 343 (19): 1350–1354. doi: 10.1056/NEJM200011093431901.CrossRefPubMedGoogle Scholar
  31. Fabrini, M.G., G. Silvano, I. Lolli, F. Perrone, A. Marsella, V. Scotti, et al. 2009. A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma. Journal of Neuro-Oncology 92 (1): 79–86. doi: 10.1007/s11060-008-9739-6.CrossRefPubMedGoogle Scholar
  32. Francisco, L.M., V.H. Salinas, K.E. Brown, V.K. Vanguri, G.J. Freeman, V.K. Kuchroo, et al. 2009. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. The Journal of Experimental Medicine 206: 3015–3029. doi:10.1084/jem.20090847.Google Scholar
  33. Galanis, E., J.C. Buckner, M.J. Maurer, J.I. Kreisberg, K. Ballman, J. Boni, et al. 2005. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group Study. Journal of Clinical Oncology 23 (23): 5294–5304. doi: 10.1200/JCO.2005.23.622.CrossRefPubMedGoogle Scholar
  34. Gera, N., A. Yang, T.S. Holtzman, S.X. Lee, E.T. Wong, and K.D. Swanson. 2015. Tumor treating fields perturb the localization of septins and cause aberrant mitotic exit. PLoS One. 10 (5): e0125269. doi: 10.1371/journal.pone.0125269.CrossRefPubMedPubMedCentralGoogle Scholar
  35. Gilbert, M.R., M. Wang, K.D. Aldape, R. Stupp, M.E. Hegi, K.A. Jaeckle, et al. 2013. Dose-dense temozolomide for newly diagnosed glioblastoma: A randomized phase III clinical trial. Journal of Clinical Oncology 31 (32): 4085–4091. doi: 10.1200/JCO.2013.49.6968.CrossRefPubMedPubMedCentralGoogle Scholar
  36. Gilbert, M.R., J.J. Dignam, T.S. Armstrong, J.S. Wefel, D.T. Blumenthal, M.A. Vogelbaum, et al. 2014. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The New England Journal of Medicine 370 (8): 699–708. doi: 10.1056/NEJMoa1308573.CrossRefPubMedPubMedCentralGoogle Scholar
  37. Gutin, P.H., F.M. Iwamoto, K. Beal, N.A. Mohile, S. Karimi, B.L. Hou, et al. 2009. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. International Journal of Radiation Oncology, Biology, Physics 75 (1): 156–163. doi: 10.1016/j.ijrobp.2008.10.043.CrossRefPubMedPubMedCentralGoogle Scholar
  38. Harrow, S., V. Papanastassiou, J. Harland, et al. 2004. HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: Safety data and long-term survival. Gene Therapy 11: 1648–1658. doi:10.1038/sj.gt.3302289.Google Scholar
  39. Hegi, M.E., A.C. Diserens, T. Gorlia, M.F. Hamou, N. de Tribolet, M. Weller, et al. 2005. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New England Journal of Medicine 352 (10): 997–1003. doi: 10.1056/NEJMoa043331.CrossRefPubMedGoogle Scholar
  40. Herrlinger, U. 2012. Gliomatosis cerebri. Handbook of Clinical Neurology 105: 507–515. doi: 10.1016/B978-0-444-53502-3.00005-7.CrossRefPubMedGoogle Scholar
  41. Hovey, E., J., Field, K., M., Rosenthal, M., Nowak, A., K., Cher, L., Wheeler, H. et al. 2015. Continuing or ceasing bevacizumab at disease progression: Results from the CABARET study, a prospective randomized phase II trial in patients with recurrent glioblastoma. 2015 ASCO Annual Meeting: American Society of Clinical Oncology.Google Scholar
  42. Immonen, A., M. Vapalahti, K. Tyynela, et al. 2004. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: A randomised, controlled study. Molecular Therapy 10: 967–972. doi: 10.1016/j.ymthe.2004.08.002.
  43. Iwamoto, F.M., L.E. Abrey, K. Beal, P.H. Gutin, M.K. Rosenblum, V.E. Reuter, L.M. DeAngelis, and A.B. Lassman. 2009. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 73 (15): 1200–1206. doi: 10.1212/WNL.0b013e3181bc0184.CrossRefPubMedPubMedCentralGoogle Scholar
  44. Keime-Guibert, F., O. Chinot, L. Taillandier, S. Cartalat-Carel, M. Frenay, G. Kantor, et al. 2007. Radiotherapy for glioblastoma in the elderly. The New England Journal of Medicine 356 (15): 1527–1535. doi: 10.1056/NEJMoa065901.CrossRefPubMedGoogle Scholar
  45. Kirson, E.D., V. Dbaly, F. Tovarys, J. Vymazal, J.F. Soustiel, A. Itzhaki, et al. 2007. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proceedings of the National Academy of Sciences of the United States of America 104 (24): 10152–10157. doi: 10.1073/pnas.0702916104.CrossRefPubMedPubMedCentralGoogle Scholar
  46. Kirson, E.D., R.S. Schneiderman, V. Dbaly, F. Tovarys, J. Vymazal, A. Itzhaki, et al. 2009a. Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields). BMC Medical Physics 9: 1. doi: 10.1186/1756-6649-9-1.CrossRefPubMedPubMedCentralGoogle Scholar
  47. Kirson, E.D., M. Giladi, Z. Gurvich, A. Itzhaki, D. Mordechovich, R.S. Schneiderman, et al. 2009b. Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs. Clinical & Experimental Metastasis 26 (7): 633–640. doi: 10.1007/s10585-009-9262-y.CrossRefGoogle Scholar
  48. Kita, D., I.F. Ciernik, S. Vaccarella, S. Franceschi, P. Kleihues, U.M. Lutolf, et al. 2009. Age as a predictive factor in glioblastomas: Population-based study. Neuroepidemiology 33 (1): 17–22. doi: 10.1159/000210017.CrossRefPubMedGoogle Scholar
  49. Kreisl, T.N., L. Kim, K. Moore, P. Duic, C. Royce, I. Stroud, et al. 2009. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. Journal of Clinical Oncology 27 (5): 740–745. doi: 10.1200/JCO.2008.16.3055.CrossRefPubMedGoogle Scholar
  50. Kubben, P.L., K.J. ter Meulen, O.E. Schijns, M.P. ter Laak-Poort, J.J. van Overbeeke, and H. van Santbrink. 2011. Intraoperative MRI-guided resection of glioblastoma multiforme: A systematic review. The Lancet Oncology 12 (11): 1062–1070. doi: 10.1016/S1470-2045(11)70130-9.CrossRefPubMedGoogle Scholar
  51. Lacroix, M., D. Abi-Said, D.R. Fourney, Z.L. Gokaslan, W. Shi, F. DeMonte, F.F. Lang, I.E. McCutcheon, S.J. Hassenbusch, E. Holland, K. Hess, C. Michael, D. Miller, and R. Sawaya. 2001. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. Journal of Neurosurgery 95 (2): 190–198. doi: 10.3171/jns.2001.95.2.0190.CrossRefPubMedGoogle Scholar
  52. Li, Y.M., D. Suki, K. Hess, and R. Sawaya. 2016. The influence of maximum safe resection of glioblastoma on survival in 1229 patients: Can we do better than gross-total resection? Journal of Neurosurgery 124 (4): 977–988. doi: 10.3171/2015.5.JNS142087.CrossRefPubMedGoogle Scholar
  53. Malmstrom, A., B.H. Gronberg, C. Marosi, R. Stupp, D. Frappaz, H. Schultz, et al. 2012. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: The Nordic randomised, phase 3 trial. The Lancet Oncology 13 (9): 916–926. doi: 10.1016/S1470-2045(12)70265-6.CrossRefPubMedGoogle Scholar
  54. Markert, J.M., M.D. Medlock, S.D. Rabkin, et al. 2000. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial. Gene Therapy 7: 867–874. doi: 10.1038/sj.gt.3301205.
  55. McKie, E.A., A.R. MacLean, A.D. Lewis, et al. 1996. Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours—evaluation of a potentially effective clinical therapy. British Journal of Cancer 74: 745–752.CrossRefPubMedPubMedCentralGoogle Scholar
  56. Miao, H., B.D. Choi, C.M. Suryadevara, L. Sanchez-Perez, S. Yang, G. De Leon, et al. 2014. EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma. PLoS One 9 (4): e94281. doi: 10.1371/journal.pone.0094281.
  57. Michaelsen, S.R., I.J. Christensen, K. Grunnet, M.T. Stockhausen, H. Broholm, M. Kosteljanetz, et al. 2013. Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: An observational study of a cohort of consecutive non-selected patients from a single institution. BMC Cancer 13: 402. doi: 10.1186/1471-2407-13-402.CrossRefPubMedPubMedCentralGoogle Scholar
  58. Minniti, G., C. Scaringi, G. Lanzetta, I. Terrenato, V. Esposito, A. Arcella, et al. 2015. Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: A propensity-matched analysis. International Journal of Radiation Oncology, Biology, Physics 91 (1): 109–115. doi: 10.1016/j.ijrobp.2014.09.013.CrossRefPubMedGoogle Scholar
  59. Muragaki, Y., T. Maruyama, H. Iseki, M. Tanaka, C. Shinohara, K. Takakura, et al. 2011. Phase I/IIa trial of autologous formalin-fixed tumor vaccine concomitant with fractionated radiotherapy for newly diagnosed glioblastoma. Journal of Neurosurgery 115: 248–255. doi: 10.3171/2011.4.JNS10377.CrossRefPubMedGoogle Scholar
  60. Nelson, D.F., M. Diener-West, J. Horton, C.H. Chang, D. Schoenfeld, and J.S. Nelson. 1988. Combined modality approach to treatment of malignant gliomas--re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: A joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group. NCI Monographs 6: 279–284.Google Scholar
  61. Nevin, S. 1938. Gliomatosis cerebri. Brain 61: 170–191.CrossRefGoogle Scholar
  62. Nwokedi, E.C., S.J. DiBiase, S. Jabbour, J. Herman, P. Amin, and L.S. Chin. 2002. Gamma knife stereotactic radiosurgery for patients with glioblastoma multiforme. Neurosurgery 50 (1): 41–46. discussion 46–7.Google Scholar
  63. Ostertag, D., K.K. Amundson, F. Lopez Espinoza, B. Martin, T. Buckley, A.P. Galvao da Silva, A.H. Lin, D.T. Valenta, O.D. Perez, C.E. Ibanez, C.I. Chen, P.L. Pettersson, R. Burnett, V. Daublebsky, J. Hlavaty, W. Gunzburg, N. Kasahara, H.E. Gruber, D.J. Jolly, and J.M. Robbins. 2012. Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector. Neuro-Oncology 14 (2): 145–159. doi: 10.1093/neuonc/nor199.CrossRefPubMedGoogle Scholar
  64. Papanastassiou, V., R. Rampling, M. Fraser, et al. 2002. The potential for efficacy of the modified (ICP 34.5(−)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: A proof of principle study. Gene Therapy 9(6): 398–406. doi: 10.1038/sj.gt.3301664.
  65. Parsa, A.T., J.S. Waldron, A. Panner, C.A. Crane, I.F. Parney, J.J. Barry, et al. 2007. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nature Medicine 13: 84–88. doi: 10.1038/nm1517.
  66. Paszat, L., N. Laperriere, P. Groome, K. Schulze, W. Mackillop, and E. Holowaty. 2001. A population-based study of glioblastoma multiforme. International Journal of Radiation Oncology, Biology, Physics 51 (1): 100–107.CrossRefPubMedGoogle Scholar
  67. Peggs, K.S., S.A. Quezada, C.A. Chambers, A.J. Korman, and J.P. Allison. 2009. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. The Journal of Experimental Medicine 206: 1717–1725. doi: 10.1084/jem.20082492.
  68. Pelloski, C.E., K.V. Ballman, A.F. Furth, L. Zhang, E. Lin, E.P. Sulman, et al. 2007. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. Journal of Clinical Oncology 25 (16): 2288–2294. doi: 10.1200/JCO.2006.08.0705.CrossRefPubMedGoogle Scholar
  69. Perry, J.R., N. Laperriere, C.J. O’Callaghan, A.A. Brandes, J. Menten, C. Phillips, M.F. Fay, R. Nishikawa, J.G. Cairncross, W. Roa, D. Osoba, A. Sahgal, H.W. Hirte, W. Wick, F. Laigle-Donadey, E. Franceschi, O.L. Chinot, C. Winch, K. Ding, and W.P. Mason. 2016. A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062-22061, TROG 08.02, NCT00482677). Journal of Clinical Oncology 34 (15, supplement (2016 ASCO Annual Meeting)):LBA2.Google Scholar
  70. Pitz, M.W., E.A. Eisenhauer, M.V. MacNeil, B. Thiessen, J.C. Easaw, D.R. Macdonald, et al. 2015. Phase II study of PX-866 in recurrent glioblastoma. Neuro-Oncology 17 (9): 1270–1274. doi: 10.1093/neuonc/nou365.PubMedPubMedCentralGoogle Scholar
  71. Pol, J.G., M. Marguerie, R. Arulanandam, et al. 2013. Panorama from the oncolytic virotherapy summit. Molecular Therapy 21: 1814–1818. doi: 10.1038/mt.2013.207.
  72. Powers, M.V., K. Jones, C. Barillari, I. Westwood, R.L. van Montfort, and P. Workman. 2010. Targeting HSP70: the second potentially druggable heat shock protein and molecular chaperone? Cell Cycle 9: 1542–1550. doi: 10.4161/cc.9.8.11204.
  73. Prins, R.M., H. Soto, Odesa S.K. KonkankitV, A. Eskin, W.H. Yong, et al. 2011. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clinical Cancer Research 17(6): 1603–1615. doi: 10.1158/1078-0432.ccr-10-2563.
  74. Quant, E.C., A.D. Norden, J. Drappatz, A. Muzikansky, L. Doherty, D. Lafrankie, A. Ciampa, S. Kesari, and P.Y. Wen. 2009. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro-Oncology 11 (5): 550–555. doi: 10.1215/15228517-2009-006.CrossRefPubMedPubMedCentralGoogle Scholar
  75. Rainov, N.G. 2000. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Human Gene Therapy 11(17): 2389–2401. doi: 10.1089/104303400750038499.
  76. Rampling, R., G. Cruickshank, V. Papanastassiou, et al. 2000. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Therapy 7: 859–866.CrossRefPubMedGoogle Scholar
  77. Reardon, D.A., G. Akabani, R.E. Coleman, A.H. Friedman, H.S. Friedman, J.E. Herndon 2nd, et al.2006. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: Phase II study results. Journal of Clinical Oncology 24 (1): 115–122. doi: 10.1200/JCO.2005.03.4082.
  78. Reifenberger, G., B. Hentschel, J. Felsberg, G. Schackert, M. Simon, O. Schnell, et al. 2012. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. International Journal of Cancer 131 (6): 1342–1350. doi: 10.1002/ijc.27385.CrossRefPubMedGoogle Scholar
  79. Roa, W., P.M. Brasher, G. Bauman, M. Anthes, E. Bruera, A. Chan, et al. 2004. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. Journal of Clinical Oncology 22 (9): 1583–1588. doi: 10.1200/JCO.2004.06.082.CrossRefPubMedGoogle Scholar
  80. Rudd, C.E., A. Taylor, and H. Schneider. 2009. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunological Reviews 229: 12–26. doi: 10.1111/j.1600-065X.2009.00770.x.
  81. Sampson, J.H., A.B. Heimberger, G.E. Archer, K.D. Aldape, A.H. Friedman, H.S. Friedman, et al. 2010. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. Journal of Clinical Oncology 28: 4722–4729. doi: 10.1200/jco.2010.28.6963.
  82. Sanai, N., M.Y. Polley, M.W. McDermott, A.T. Parsa, and M.S. Berger. 2011. An extent of resection threshold for newly diagnosed glioblastomas. Journal of Neurosurgery 115 (1): 3–8. doi: 10.3171/2011.2.JNS10998.CrossRefPubMedGoogle Scholar
  83. Sandmair, A.M., S. Loimas, P. Puranen, et al. 2000. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Human Gene Therapy 11(16): 2197–2205. doi: 10.1089/104303400750035726.
  84. Schwartz, R.H. 1992. Costimulation of T lymphocytes: The role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71: 1065–1068.CrossRefPubMedGoogle Scholar
  85. Seystahl, K., W. Wick, and M. Weller. 2016. Therapeutic options in recurrent glioblastoma–An update. Critical Reviews in Oncology/Hematology 99: 389–408. doi: 10.1016/j.critrevonc.2016.01.018.CrossRefPubMedGoogle Scholar
  86. Sloan, A.E., M.S. Ahluwalia, J. Valerio-Pascua, S. Manjila, M.G. Torchia, S.E. Jones, et al. 2013. Results of the NeuroBlate System first-in-humans Phase I clinical trial for recurrent glioblastoma: Clinical article. Journal of Neurosurgery 118 (6): 1202–1219. doi: 10.3171/2013.1.JNS1291.CrossRefPubMedGoogle Scholar
  87. Souhami, L., W. Seiferheld, D. Brachman, E.B. Podgorsak, M. Werner-Wasik, R. Lustig, et al. 2004. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: Report of Radiation Therapy Oncology Group 93-05 protocol. International Journal of Radiation Oncology, Biology, Physics 60 (3): 853–860. doi: 10.1016/j.ijrobp.2004.04.011.CrossRefPubMedGoogle Scholar
  88. Stark-Vance, V. 2005. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neuro-Oncology 7: 369.Google Scholar
  89. Stummer, W., U. Pichlmeier, T. Meinel, O.D. Wiestler, F. Zanella, H.J. Reulen, et al. 2006. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: A randomised controlled multicentre phase III trial. The Lancet Oncology 7 (5): 392–401. doi: 10.1016/S1470-2045(06)70665-9.CrossRefPubMedGoogle Scholar
  90. Stupp, R., W.P. Mason, M.J. van den Bent, M. Weller, B. Fisher, M.J. Taphoorn, et al. 2005. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England Journal of Medicine 352 (10): 987–996. doi: 10.1056/NEJMoa043330.CrossRefPubMedGoogle Scholar
  91. Stupp, R., M.E. Hegi, W.P. Mason, M.J. van den Bent, M.J. Taphoorn, R.C. Janzer, et al. 2009. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. The Lancet Oncology 10 (5): 459–466. doi: 10.1016/S1470-2045(09)70025-7.CrossRefPubMedGoogle Scholar
  92. Stupp, R., E.T. Wong, A.A. Kanner, D. Steinberg, H. Engelhard, V. Heidecke, et al. 2012. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality. European Journal of Cancer 48 (14): 2192–2202. doi: 10.1016/j.ejca.2012.04.011.CrossRefPubMedGoogle Scholar
  93. Stupp, R., S. Taillibert, A.A. Kanner, S. Kesari, D.M. Steinberg, S.A. Toms, et al. 2015. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: A randomized clinical trial. Journal of the American Medical Association 314 (23): 2535–2543. doi: 10.1001/jama.2015.16669.CrossRefPubMedGoogle Scholar
  94. Suchorska, B., M. Weller, G. Tabatabai, C. Senft, P. Hau, M.C. Sabel, et al. 2016. Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial. Neuro-Oncology 18 (4): 549–556. doi: 10.1093/neuonc/nov326.CrossRefPubMedPubMedCentralGoogle Scholar
  95. Taal, W., H.M. Oosterkamp, A.M. Walenkamp, H.J. Dubbink, L.V. Beerepoot, M.C. Hanse, et al. 2014. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): A randomised controlled phase 2 trial. The Lancet Oncology 15 (9): 943–953. doi: 10.1016/S1470-2045(14)70314-6.CrossRefPubMedGoogle Scholar
  96. Taillibert, S., C. Chodkiewicz, F. Laigle-Donadey, M. Napolitano, S. Cartalat-Carel, and M. Sanson. 2006. Gliomatosis cerebri: A review of 296 cases from the ANOCEF database and the literature. Journal of Neuro-Oncology 76 (2): 201–205. doi: 10.1007/s11060-005-5263-0.CrossRefPubMedGoogle Scholar
  97. Thaci, B., C.E. Brown, E. Binello, K. Werbaneth, P. Sampath, and S. Sengupta. 2014. Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy. Neuro-Oncology 16 (10): 1304–1312.CrossRefPubMedPubMedCentralGoogle Scholar
  98. Tolcher, A.W., S.L. Gerson, L. Denis, C. Geyer, L.A. Hammond, A. Patnaik, et al. 2003. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. British Journal of Cancer 88 (7): 1004–1011. doi: 10.1038/sj.bjc.6600827.CrossRefPubMedPubMedCentralGoogle Scholar
  99. Torok, J.A., R.E. Wegner, A.H. Mintz, D.E. Heron, and S.A. Burton. 2011. Re-irradiation with radiosurgery for recurrent glioblastoma multiforme. Technology in Cancer Research & Treatment 10 (3): 253–258.Google Scholar
  100. Vauleon, E., T. Avril, B. Collet, J. Mosser, and V. Quillien. 2010. Overview of cellular immunotherapy for patients with glioblastoma. Clinical & Developmental Immunology 2010: 689171. doi: 10.1155/2010/689171.
  101. Velu, V., K. Titanji, B. Zhu, S. Husain, A. Pladevega, L. Lai, et al. 2009. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 458(7235): 206–210. doi: 10.1038/nature07662.
  102. Vuorinen, V., S. Hinkka, M. Farkkila, and J. Jaaskelainen. 2003. Debulking or biopsy of malignant glioma in elderly people – a randomised study. Acta Neurochirurgica 145 (1): 5–10. doi: 10.1007/s00701-002-1030-6.CrossRefPubMedGoogle Scholar
  103. Walker, M.D., E. Alexander Jr., W.E. Hunt, C.S. MacCarty, M.S. Mahaley Jr., J. Mealey Jr., et al. 1978. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. Journal of Neurosurgery 49 (3): 333–343. doi: 10.3171/jns.1978.49.3.0333.CrossRefPubMedGoogle Scholar
  104. Walker, M.D., S.B. Green, D.P. Byar, E. Alexander Jr., U. Batzdorf, W.H. Brooks, et al. 1980. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. The New England Journal of Medicine 303 (23): 1323–1329. doi: 10.1056/NEJM198012043032303.CrossRefPubMedGoogle Scholar
  105. Wallner, K.E., J.H. Galicich, G. Krol, E. Arbit, and M.G. Malkin. 1989. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. International Journal of Radiation Oncology, Biology, Physics 16 (6): 1405–1409.CrossRefPubMedGoogle Scholar
  106. Weller, M., T. Cloughesy, J.R. Perry, and W. Wick. 2013. Standards of care for treatment of recurrent glioblastoma–are we there yet? Neuro-Oncology 15 (1): 4–27. doi: 10.1093/neuonc/nos273.CrossRefPubMedGoogle Scholar
  107. Wen, P.Y., A. Omuro, M.S. Ahluwalia, H.M. Fathallah-Shaykh, N. Mohile, J.J. Lager, et al. 2015. Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma. Neuro-Oncology 17 (9): 1275–1283. doi: 10.1093/neuonc/nov083.CrossRefPubMedPubMedCentralGoogle Scholar
  108. Westphal, M., D.C. Hilt, E. Bortey, P. Delavault, R. Olivares, P.C. Warnke, et al. 2003. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-Oncology 5 (2): 79–88. doi: 10.1215/S1522-8517-02-00023-6.PubMedPubMedCentralGoogle Scholar
  109. Westphal, M., Z. Ram, V. Riddle, D. Hilt, E. Bortey, and Executive Committee of the Gliadel Study G. 2006. Gliadel wafer in initial surgery for malignant glioma: Long-term follow-up of a multicenter controlled trial. Acta Neurochirurgica 148 (3): 269–275. doi: 10.1007/s00701-005-0707-z.discussion 275
  110. Westphal, M., O. Heese, J.P. Steinbach, O. Schnell, G. Schackert, M. Mehdorn, et al. 2015. A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma. European Journal of Cancer 51 (4): 522–532. doi: 10.1016/j.ejca.2014.12.019.CrossRefPubMedGoogle Scholar
  111. Wick, W., V.K. Puduvalli, M.C. Chamberlain, M.J. van den Bent, A.F. Carpentier, L.M. Cher, et al. 2010. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. Journal of Clinical Oncology 28 (7): 1168–1174. doi: 10.1200/JCO.2009.23.2595.CrossRefPubMedPubMedCentralGoogle Scholar
  112. Wick, W., T. Gorlia, P. Bady, M. Platten, M.J. van den Bent, M.J. Taphoorn, et al. 2016. Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082). Clinical Cancer Research. doi: 10.1158/1078-0432.CCR-15-3153.Google Scholar
  113. Wilson, E.H., W. Weninger, and C.A. Hunter. 2010. Trafficking of immune cells in the central nervous system. The Journal of Clinical Investigation 120: 1368–1379. doi:10.1172/jci41911.Google Scholar
  114. Wing, K., Y. Onishi, P. Prieto-Martin, T. Yamaguchi, M. Miyara, Z. Fehervari, et al. 2008. CTLA-4 control over Foxp3+ regulatory T cell function. Science 322 (5899): 271–275. doi: 10.1126/science.1160062.
  115. Wong, A.J., J.M. Ruppert, S.H. Bigner, C.H. Grzeschik, P.A. Humphrey, D.S. Bigner, et al. 1992. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proceedings of the National Academy of Sciences of the United States of America 89: 2965–2969. doi: 10.1073/pnas.89.7.2965.CrossRefPubMedPubMedCentralGoogle Scholar
  116. Wong, E.T., E. Lok, and K.D. Swanson. 2015. An evidence-based review of alternating electric fields therapy for malignant gliomas. Current Treatment Options in Oncology 16 (8): 40. doi: 10.1007/s11864-015-0353-5.CrossRefPubMedPubMedCentralGoogle Scholar
  117. Yang, L., R. Hwang, Y. Chiang, et al. 1998. Mechanisms for ganciclovir resistance in gastrointestinal tumor cells transduced with a retroviral vector containing the herpes simplex virus thymidine kinase gene. Clinical Cancer Research 4: 731–741.Google Scholar
  118. Yong, R.L., T. Wu, N. Mihatov, M.J. Shen, M.A. Brown, K.A. Zaghloul, et al. 2014. Residual tumor volume and patient survival following reoperation for recurrent glioblastoma. Journal of Neurosurgery 121 (4): 802–809. doi: 10.3171/2014.6.JNS132038.CrossRefPubMedGoogle Scholar
  119. Young, J.C., V.R. Agashe, K. Siegers, and F.U. Hartl. 2004. Pathways of chaperone-mediated protein folding in the cytosol. Nature Reviews. Molecular Cell Biology 5 (10): 781–791. doi: 10.1038/nrm1492.
  120. Zalutsky, M.R., D.A. Reardon, G. Akabani, R.E. Coleman, A.H. Friedman, H.S. Friedman, et al. 2008. Clinical experience with alpha-particle emitting 211At: Treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. Journal of Nuclear Medicine 49 (1): 30–38. doi: 10.2967/jnumed.107.046938.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Division of Neuro-oncologyThe Ohio State University Comprehensive Cancer CenterColumbusUSA

Personalised recommendations